Results 251 to 260 of about 769,731 (345)

Promoter Hypermethylation‐Induced Silencing of FXYD1 Drives Breast Cancer Metastasis via DDX5‐Mediated Wnt/β‐Catenin Pathway Activation

Advanced Science, EarlyView.
This study identifies FXYD1 as an epigenetically silenced tumor suppressor in breast cancer. DNA methylation turns off the gene FXYD1 in breast cancer, and low levels predict worse outcomes. Restoring FXYD1 limits breast cancer cells proliferation and metastasis. In the nucleus, FXYD1 recruits the E3 ligase MAEA to K63‐ubiquitinate DDX5 for proteasomal
Ping Wen, Fanli Qu, Long Wang, Qing Shao, Sisi Li, Yang Qin, Dongping Jiang, Senmiao Zhang, Jiangdong Sui, Guanwen Wang, Ningning Zhang, Xiaohua Zeng   +11 more
wiley   +1 more source

Nitric oxide-dependent stabilization of vimentin confers chemoresistance in ovarian cancer. [PDF]

Mol Ther Nucleic Acids
Melone G, Bayraktar R, Zhao H, Hynes SO, Kaar F, Freegrove A, Deng J, Baseviciene A, Uzair I, Martinez KO, Guzman-Rojas L, Chervo MF, Li M, Qian W, Zhou J, Phillips A, Zambo KDA, Nikolos F, Chan KS, Thomas C, Francis L, Chang JC.   +21 more
europepmc   +1 more source

Decision letter for "Establishment and Characterization of an <i>In Vitro</i> <scp>3D</scp> Ovarian Cancer Model for Drug Screening Assays"

, 2020

openalex   +1 more source

Enhancing CAR‐T Cell Efficacy in Solid Tumors by Inhibiting CCL5/VEGF‐Mediated Angiogenesis

Advanced Science, EarlyView.
This study reveals that CAR‐T cells in solid tumors produce CCL5, which paradoxically induces VEGF and angiogenesis to promote tumor growth. Blocking CCL5/VEGF signaling—through gene knockout, or the CCR5 inhibitor maraviroc—significantly enhances the antitumor efficacy of CAR‑T therapy (the diagram was created in Biorender).
Shishuo Sun, Qihong Li, Bixi Wang, Gang Wang, Ying Xue, Yibing Liang, Chenhe Hu, Zhenyu Wang, Xiaoge Gao, Haiheng Xu, Jun Song, Hailong Li, Liantao Li, Xiaoxiao Liu, Patrick Ming‐Kuen Tang, Qing Zhang   +15 more
wiley   +1 more source

Residential Radon Levels and Ovarian Cancer Among Postmenopausal Women.

JAMA Netw Open
Williamson MR, Whitsel EA, Smith RL, Collins JM, Stewart JD, Jung SY, Harris HR, Feiler MO, Manson JE, Qi L, Schwartz GG.   +10 more
europepmc   +1 more source

Treatment of HRD-positive elderly ovarian cancer patient: a case report. [PDF]

Anticancer Drugs
Jiang Y, Yi Q, Wang Y, Li C, Liu H.
europepmc   +1 more source

Effect of the BRCA1-SIRT1-EGFR axis on cisplatin sensitivity in ovarian cancer.

, 2016
Da Li, Qi‐Jun Wu, Fangfang Bi, Si-Lei Chen, Yiming Zhou, Yue Zhao, Qing Yang   +6 more
openalex  

One‐Step Glycoengineering of NK Cells With High‐Affinity Siglec Ligands for Cancer Immunotherapy

Advanced Science, EarlyView.
This study develops an engineered NmCSS enzyme with improved activity for bulky group modified sialic acids, enabling efficient synthesis of structurally diverse sialoside analogs in a single step. Glycan microarray screening identified Siglec high‐affinity ligands, which were incorporated onto natural killer (NK) cells via a one‐pot enzymatic system ...
Shuai Hu, Ben Huang, Lingyan Wang, Qiang Guo, Cuiping Jiang, Ruicheng Qi, Shuyao Wang, Lin‐Tai Da, Wenjie Peng   +8 more
wiley   +1 more source

Prevalence and Management of Nonepithelial Ovarian Cancer in a Sub-Saharan African Setting. [PDF]

Obstet Gynecol Int
Batu BG, Wondafrash M, Teka AY, Lucero-Prisno DE, Sium AF.   +4 more
europepmc   +1 more source